Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.75
Bid: 42.00
Ask: 43.50
Change: 1.75 (4.27%)
Spread: 1.50 (3.571%)
Open: 42.25
High: 43.00
Low: 41.00
Prev. Close: 41.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
6 May 2020 17:18

Avacta Group Reports Widened Loss Amid Higher Operating Expenses

Avacta Group Reports Widened Loss Amid Higher Operating Expenses

Read more
1 May 2020 13:28

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

Read more
1 May 2020 13:17

Avacta to collaborate with Adeptrix on Covid-19 tests

(Sharecast News) - Biotherapeutics developer Avacta has entered into a collaboration agreement with American firm Adeptrix to develop a high throughput Covid-19 antigen test using its proprietary bead-assisted mass spectrometry (BAMS) platform.

Read more
29 Apr 2020 16:13

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
22 Apr 2020 15:40

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

Read more
22 Apr 2020 14:50

Avacta shares surge on progress with Covid test

(Sharecast News) - Avacta Group said on Wednesday that, in four weeks and "well ahead" of schedule, it had successfully generated multiple 'Affimer' reagents that bound the SARS-COV-2 viral antigen as part of the collaboration with Cytiva - formerly GE Healthcare Life Sciences - to develop an Affimer-based rapid test for the Covid-19 coronavirus infection.

Read more
14 Apr 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
8 Apr 2020 10:41

Avacta To Co-Develop Test That Can Diagnose Covid-19 In Minutes

Avacta To Co-Develop Test That Can Diagnose Covid-19 In Minutes

Read more
7 Apr 2020 07:31

Avacta Raises More-Than-Expected GBP3.8 Million In Share Placing

Avacta Raises More-Than-Expected GBP3.8 Million In Share Placing

Read more
6 Apr 2020 12:42

Avacta raises ?3.75m, expects minimal impact from pandemic

(Sharecast News) - Biotherapeutics company Avacta Group announced on Monday that, in response to "substantial" institutional interest, it has conditionally raised gross proceeds of ?3.75m under a placing, through the issue of 20,833,333 new ordinary shares at a price of 18p each.

Read more
2 Apr 2020 14:55

Avacta Announces GBP2 Million Subscription With Two Subscribers

Avacta Announces GBP2 Million Subscription With Two Subscribers

Read more
3 Feb 2020 15:22

Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell

Avacta Inks Cell And Gene Therapy Deal With Joint Venture AffyXell

Read more
3 Feb 2020 10:17

Avacta signs collaboration deal with Daewoong joint venture

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group announced on Monday that it has signed a collaboration and license agreement with AffyXell Therapeutics - the recently-established joint venture with Daewoong Pharmaceutical - to develop Affimer proteins to be used by AffyXell for the generation of new cell and gene therapies.

Read more
28 Jan 2020 11:57

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Read more
23 Jan 2020 12:44

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.